Shares of Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) were down 18.6% as of 11:50 a.m. EDT on Friday. The big tumble followed yesterday's huge gain, which stemmed from news that the clinical-stage biotech made a deal for exclusive worldwide rights to develop and market drugs based on more than 600 compounds targeting the endocannabinoid system.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,